Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03830164 · ClinicalTrials.gov registry record · Phase 2
Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03830164: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03830164 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03830164, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This phase II trial studies how well pentoxifylline, atorvastatin, and vitamin E (PAVE) work in treating patients with erectile dysfunction after radiation therapy for prostate cancer. Atorvastatin may reduce high cholesterol. Pentoxifylline and vitamin E may enhance blood flow. Giving PAVE may work better in treating prostate cancer patients with post-radiation therapy erectile dysfunction.
Interventions
- DRUG Pentoxifylline
- DRUG Atorvastatin
- DIETARY_SUPPLEMENT Vitamin E Compound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2022-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03830164
The ClinicalTrials.gov registry entry for NCT03830164 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pentoxifylline is the first listed.
NCT03830164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03830164 about?
NCT03830164 is a clinical study titled "Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer". This phase II trial studies how well pentoxifylline, atorvastatin, and vitamin E (PAVE) work in treating patients with erectile dysfunction after radiation therapy for prostate cancer. Atorvastatin may reduce high cholesterol. Pentoxifylline and vitamin E may enhance blood flow. Giving PAVE may work...
What is the current status of trial NCT03830164?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2019-11-20. Estimated completion is 2022-11-02.
What interventions are being tested in trial NCT03830164?
The interventions under investigation include: Pentoxifylline (DRUG), Atorvastatin (DRUG), Vitamin E Compound (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03830164?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.